Fangzhou Wins Gilead ‘Award of Excellence' for AI-Driven Chronic Disease Management
SHANGHAI, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, received the “Excellence Award” at Gilead S...
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
Gilead Sciences (GILD) reached $112.26 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.
Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Gilead Sciences (GILD) closed at $117.86, marking a +2.26% move from the previous day.
Gilead Sciences, Inc. (GILD) Presents At Baird Global Healthcare Conference 2025 Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Baird Global Healthcare Conference 2025 September 10, 2025 11:25 AM EDT Company Participants Cindy Perettie - Executive Vice President of Kite Conference Call P...
Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Daniel O'Day - Chairman & CEO Johanna Mercier - Chie...
US plans to bring Gilead HIV drug to market in high-burden HIV countries
The U.S. State Department announced a plan on Thursday to bring Gilead Sciences Inc's drug lenacapavir to market "at cost" in high-burden HIV countries in an effort to reach 2 million people over t...
Gilead Sciences: HIV Leadership Outshines Decline In COVID-19 Drug Sales
Despite retail investors' cautious attitude toward Gilead Sciences, it once again beat analysts' expectations by a wide margin. In my estimation, Gilead's main star remains Biktarvy, which leaves c...
Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew D. Dickinson - Chief Financial Officer Daniel P.
EU regulator backs Gilead's twice-yearly injection for HIV prevention
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents, the drugmaker said o...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advise...
AHF: Gilead's Greed Costs Latin America HIV Protection
MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HI...
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are ad...
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention
GILD wins FDA approval for Yeztugo, the first and only twice-yearly injectable PrEP for HIV prevention in the United States.
GILD ALERT: Ongoing Investigation Into Gilead Sciences, Inc. - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerni...
Related Companies